| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.63 [0.31, 1.28] | | < 1 | | 95% | 4 studies (4/-) | 89.7 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.71 [0.41, 1.20] | | < 1 | | 95% | 3 studies (3/-) | 90.0 % | low | not evaluable | high | important | - |
| PFS (extension) | 0.66 [0.34, 1.26] | | < 1 | | 97% | 3 studies (3/-) | 89.7 % | low | not evaluable | high | important | - |
| progression or deaths (PFS) | 0.62 [0.34, 1.10] | | < 1 | | 96% | 4 studies (4/-) | 94.8 % | low | not evaluable | high | important | - |
| DOR (extension) | 3.45 [1.46, 8.18] | | > 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 2.35 [0.77, 7.20] | | > 1 | | 96% | 4 studies (4/-) | 93.3 % | low | not evaluable | high | non important | - |
| objective responses (ORR) (extension) | 1.38 [0.16, 11.98] | | > 1 | | 99% | 3 studies (3/-) | 61.5 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.78 [0.34, 1.76] | | < 1 | | 0% | 1 study (1/-) | 72.7 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 0.84 [0.56, 1.25] | | < 1 | | 0% | 1 study (1/-) | 80.5 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.55 [0.28, 1.10] | | < 1 | | 0% | 1 study (1/-) | 95.5 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 0.61 [0.29, 1.28] | | < 1 | | 0% | 1 study (1/-) | 90.5 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 0.73 [0.49, 1.10] | | < 1 | | 0% | 1 study (1/-) | 93.1 % | NA | not evaluable | | non important | - |
| SAE (grade 3-4) | 0.74 [0.47, 1.17] | | < 1 | | 0% | 1 study (1/-) | 90.4 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.06 [0.54, 2.07] | | < 1 | | 0% | 1 study (1/-) | 43.8 % | NA | not evaluable | | non important | - |
| STRAE (grade 3-4) | 0.99 [0.44, 2.27] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.66 [0.33, 1.34] | | < 1 | | 83% | 3 studies (3/-) | 87.2 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 0.45 [0.19, 1.05] | | < 1 | | 92% | 3 studies (3/-) | 96.8 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 1.00 [0.06, 15.97] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 0.38 [0.11, 1.30] | | < 1 | | 94% | 2 studies (2/-) | 93.8 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 0.32 [0.12, 0.82] | | < 1 | | 86% | 2 studies (2/-) | 99.1 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.45 [0.06, 3.23] | | < 1 | | 0% | 3 studies (3/-) | 78.6 % | low | not evaluable | high | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.64 [0.12, 3.54] | | < 1 | | 33% | 2 studies (2/-) | 69.4 % | low | not evaluable | high | non important | - |
| Alopecia TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.83 [0.14, 4.80] | | < 1 | | 0% | 3 studies (3/-) | 58.3 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 0.63 [0.13, 3.11] | | < 1 | | 0% | 3 studies (3/-) | 71.6 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 0.11 [0.05, 0.26] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | non important | - |
| Constipation TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 2.88 [0.42, 19.52] | | < 1 | | 0% | 3 studies (3/-) | 14.1 % | low | not evaluable | high | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.32 [0.05, 2.23] | | < 1 | | 0% | 3 studies (3/-) | 87.3 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.42 [0.22, 0.81] | | < 1 | | 23% | 3 studies (3/-) | 99.5 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 1.00 [0.10, 9.60] | | < 1 | | 0% | 3 studies (3/-) | 50.1 % | low | not evaluable | high | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.58 [0.09, 3.80] | | < 1 | | 0% | 2 studies (2/-) | 71.6 % | low | not evaluable | high | non important | - |
| Fatigue TRAE (grade 3-4) | 0.38 [0.14, 1.03] | | < 1 | | 6% | 3 studies (3/-) | 97.1 % | low | not evaluable | high | non important | - |
| Headache TRAE (grade 3-4) | 0.45 [0.06, 3.24] | | < 1 | | 0% | 3 studies (3/-) | 78.6 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 0.22 [0.02, 2.32] | | < 1 | | 0% | 2 studies (2/-) | 89.4 % | low | not evaluable | high | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.58 [0.08, 4.11] | | < 1 | | 0% | 3 studies (3/-) | 70.4 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.20 [0.04, 0.90] | | < 1 | | 0% | 2 studies (2/-) | 98.2 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.75 [0.09, 6.48] | | < 1 | | 0% | 3 studies (3/-) | 60.1 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 0.50 [0.10, 2.63] | | < 1 | | 59% | 3 studies (3/-) | 79.2 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.48 [0.10, 2.26] | | < 1 | | 69% | 3 studies (3/-) | 82.3 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.65 [0.22, 1.94] | | < 1 | | 78% | 2 studies (2/-) | 77.8 % | low | not evaluable | high | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.12 [0.01, 2.33] | | < 1 | | 0% | 1 study (1/-) | 91.7 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.68 [0.20, 2.35] | | < 1 | | 0% | 3 studies (3/-) | 72.9 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 1.23 [0.19, 8.14] | | < 1 | | 0% | 3 studies (3/-) | 41.4 % | low | not evaluable | high | non important | - |
| Nausea TRAE (grade 3-4) | 0.20 [0.03, 1.28] | | < 1 | | 0% | 3 studies (3/-) | 95.5 % | low | not evaluable | high | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.05 [0.00, 0.92] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.16 [0.01, 3.29] | | < 1 | | 0% | 1 study (1/-) | 87.9 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.51 [0.09, 2.98] | | < 1 | | 0% | 2 studies (2/-) | 77.0 % | low | not evaluable | high | non important | - |
| Pruritic rash TRAE (grade 3-4) | 1.00 [0.06, 15.97] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 0.46 [0.10, 2.07] | | < 1 | | 0% | 3 studies (3/-) | 84.4 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.38 [0.06, 2.56] | | < 1 | | 0% | 3 studies (3/-) | 83.8 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 0.22 [0.05, 0.93] | | < 1 | | 10% | 3 studies (3/-) | 98.0 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.05 [0.00, 0.82] | | < 1 | | 0% | 1 study (1/-) | 98.1 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.67 [0.05, 8.75] | | < 1 | | 0% | 2 studies (2/-) | 61.9 % | low | not evaluable | high | non important | - |
| Vitiligo TRAE (grade 3-4) | 1.65 [0.21, 12.82] | | < 1 | | 0% | 3 studies (3/-) | 31.7 % | low | not evaluable | high | non important | - |
| Vomiting TRAE (grade 3-4) | 0.40 [0.09, 1.67] | | < 1 | | 0% | 3 studies (3/-) | 89.5 % | low | not evaluable | high | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.67 [0.05, 8.74] | | < 1 | | 0% | 2 studies (2/-) | 61.9 % | low | not evaluable | high | non important | - |
